Trial Profile
An Exploratory study of single and repeat-dose subcutaneous administration of Otelixizumab in patients with new-onset Type I Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 31 Mar 2017 New trial record